LeBron James Inks 2-Year, 9-Figure Deal With The Los Angeles Lakers [VIDEO]

Must-Watch Films for an All-American Holiday

All five answers to the questions below have something in common. Can you figure it out?

Last year, when Jennifer Hernandez received notice that the mortgage payments on her Houston home would jump about $2,000 per month, she was stunned. Hernandez refinanced her home loan in 2016 using an adjustable-rate mortgage loan, which has a low introductory rate for a fixed initial period. Unlike the more popular fixed-rate mortgage loans, ARMs can offer temporary relief for homebuyers who want to avoid paying higher mortgage rates — however, they also come with risk. After the...

Joe Biden’s infirmities and their contributions to the president’s maladroit performance have imposed a paradox on the country. The Democratic Party has been reduced to making the negative case for Biden — not that he is a particularly adept president or that his presence in the Oval Office is desirable in itself, but that he is a better steward of the executive branch than Donald Trump. That wouldn’t be a remarkable strategy for an unpopular incumbent save the fact that the incumbent and...

The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease.  Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease, according to a press release from the company. Eligible patients include those with mild cognitive impairment (MCI) and those who have mild dementia with confirmed amyloid pathology. This is the first medication to target amyloid...

The Food and Drug Administration on Tuesday approved Eli Lilly’s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S. The agency approved the treatment, which will be sold under the brand name Kisunla, for adults with early symptomatic Alzheimer’s disease, according to the company. Nearly 7 million Americans have the condition, the fifth-leading cause of death for adults over 65, according to the Alzheimer’s...

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar...